keyword
MENU ▼
Read by QxMD icon Read
search

Remimazolam

keyword
https://www.readbyqxmd.com/read/27496519/remimazolam-pharmacologic-considerations-and-clinical-role-in-anesthesiology
#1
REVIEW
Alexandra M Wesolowski, Michael P Zaccagnino, Raymond J Malapero, Alan D Kaye, Richard D Urman
Midazolam, fentanyl, and propofol are commonly used for sedation in modern anesthesia practice. These agents possess characteristics that have afforded various anesthetics to be delivered and produce relatively safe and effective outcomes. However, each agent has certain drawbacks in clinical practice. Remimazolam, a novel benzodiazepine created out of so-called soft drug development, is an ultrashort-acting intravenous sedative-hypnotic currently being investigated in clinical trials. In this review, we evaluate the recent literature on the use of remimazolam in clinical practice as compared with current sedative agents, and we describe its potential roles for use in sedation...
September 2016: Pharmacotherapy
https://www.readbyqxmd.com/read/26363333/a-phase-iib-study-comparing-the-safety-and-efficacy-of-remimazolam-and-midazolam-in-patients-undergoing-colonoscopy
#2
Daniel J Pambianco, Keith M Borkett, Dennis S Riff, Peter J Winkle, Howard I Schwartz, Timothy I Melson, Karin Wilhelm-Ogunbiyi
BACKGROUND AND AIMS: Remimazolam is an ultra-short-acting benzodiazepine currently being developed for procedural sedation and for induction and maintenance of anesthesia. This trial was the fourth study for procedural sedation. The aim was to compare the safety and efficacy profile of remimazolam and to refine suitable doses for subsequent phase III studies in this indication. METHODS: This was a randomized, double-blind, parallel group, active controlled clinical trial with 162 male and female patients, aged 18 to 70, scheduled to undergo a routine colonoscopy...
May 2016: Gastrointestinal Endoscopy
https://www.readbyqxmd.com/read/26356290/adult-procedural-sedation-an-update
#3
REVIEW
Massimo Lamperti
PURPOSE OF REVIEW: The increasing request for procedural sedation will create in the upcoming future the need for a specific training in delivering care to patients in a continuum of sedation, whose effects and adverse events are unpredictable. The main debate in the past years has been focused on using drugs that could have few adverse effects and could be considered well tolerated when administered by a nonanaesthesiologist. Propofol remains the most used drug for procedural sedation, but given its side-effects, its administration is limited and suggested only when an anaesthesiologist is available...
December 2015: Current Opinion in Anaesthesiology
https://www.readbyqxmd.com/read/26133280/sedative-medications-outside-the-operating-room-and-the-pharmacology-of-sedatives
#4
REVIEW
Tom G Hansen
PURPOSE OF REVIEW: There is a growing medical demand for suitable sedatives and analgesics to support the ongoing progress in diagnostic procedures and imaging techniques. This review provides an update of the pharmacology of the most commonly used drugs used for these procedures and shortly mention new drugs on the horizon. RECENT FINDINGS: There are many drugs available for procedural sedation; however, they all have drawbacks and shortcomings. Multiple adverse effects are associated with the use of these agents, hence monitoring is essential, and emergency equipment should be readily available...
August 2015: Current Opinion in Anaesthesiology
https://www.readbyqxmd.com/read/25807020/fospropofol-and-remimazolam
#5
REVIEW
Romina G Ilic
No abstract text is available yet for this article.
2015: International Anesthesiology Clinics
https://www.readbyqxmd.com/read/25502841/a-phase-iia-randomized-double-blind-study-of-remimazolam-cns-7056-versus-midazolam-for-sedation-in-upper-gastrointestinal-endoscopy
#6
RANDOMIZED CONTROLLED TRIAL
Keith M Borkett, Dennis S Riff, Howard I Schwartz, Peter J Winkle, Daniel J Pambianco, James P Lees, Karin Wilhelm-Ogunbiyi
BACKGROUND: This exploratory study was the first study of remimazolam in patients to assess the safety and efficacy of different single doses for procedural sedation. METHODS: Patients scheduled to undergo a diagnostic upper gastrointestinal endoscopy were randomized to receive 1 of 3 doses of remimazolam or midazolam (25 per group) in a double-blind manner. After a single dose of study drug to achieve sedation, patients underwent gastroscopy. We assessed the success of the procedure, sedation levels, recovery from sedation, and safety...
April 2015: Anesthesia and Analgesia
https://www.readbyqxmd.com/read/25486614/simultaneous-determination-of-remimazolam-and-its-carboxylic-acid-metabolite-in-human-plasma-using-ultra-performance-liquid-chromatography-tandem-mass-spectrometry
#7
Ying Zhou, Hongyun Wang, Ji Jiang, Pei Hu
A robust and validated method based on ultra-performance liquid chromatography coupled with tandem mass spectrometry (UPLC-MS/MS) has been developed for the simultaneous determination of remimazolam, which is a new chemical entity, and its major carboxylic acid metabolite (M1) in human plasma. Plasma samples were pre-purified by protein precipitation procedure and analyzed using an isocratic chromatographic separation over an Acquity UPLC CSH C18 column. The mobile phase consisted of acetonitrile-water containing 10mM ammonium formate and 0...
January 22, 2015: Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
https://www.readbyqxmd.com/read/25422614/propofol-alternatives-in-gastrointestinal-endoscopy-anesthesia
#8
REVIEW
Basavana Gouda Goudra, Preet Mohinder Singh
Although propofol has been the backbone for sedation in gastrointestinal endoscopy, both anesthesiologists and endoscopists are faced with situations where an alternative is needed. Recent national shortages forced many physicians to explore these options. A midazolam and fentanyl combination is the mainstay in this area. However, there are other options. The aim of this review is to explore these options. The future would be, invariably, to move away from propofol. The reason is not in any way related to the drawbacks of propofol as a sedative...
October 2014: Saudi Journal of Anaesthesia
https://www.readbyqxmd.com/read/25191193/remimazolam-the-future-of-its-sedative-potential
#9
REVIEW
Basavana Gouda Goudra, Preet Mohinder Singh
Remimazolam (CNS 7056) is a new drug innovation in anesthesia. It combines the properties of two unique drugs already established in anesthesia - Midazolam and remifentanil. It acts on GABA receptors like midazolam and has organ-independent metabolism like remifentanil. It is likely to be the sedative of the future, as preliminary phase II trials have shown minimal residual effects on prolonged infusions. It has potential to be used as a sedative in ICU and as a novel agent for procedural sedation. Unlike most rapidly acting intravenous sedatives available presently, the propensity to cause apnea is very low...
July 2014: Saudi Journal of Anaesthesia
https://www.readbyqxmd.com/read/24974571/recent-advances-in-the-design-and-development-of-soft-drugs
#10
REVIEW
P Buchwald, N Bodor
This paper summarizes recent developments in the field of soft drug development as collected and reviewed for the 9th Retrometabolism-Based Drug Design and Targeting Conference. Soft drugs are still often confused with prodrugs because they both require metabolic transformations; however, they are conceptual opposites: whereas, prodrugs are pharmacologically inactive and are converted by a predictable mechanism to the active drug, soft drugs are active therapeutic agents as such and are designed to undergo a predictable and controllable metabolic deactivation after exerting their desired therapeutic effect...
June 2014: Die Pharmazie
https://www.readbyqxmd.com/read/24108261/a-phase-ib-dose-finding-study-of-multiple-doses-of-remimazolam-cns-7056-in-volunteers-undergoing-colonoscopy
#11
RANDOMIZED CONTROLLED TRIAL
Mark T Worthington, Laurie J Antonik, D Ronald Goldwater, James P Lees, Karin Wilhelm-Ogunbiyi, Keith M Borkett, Mack C Mitchell
BACKGROUND: We performed the first multiple dose study of remimazolam designed to assess both the feasibility of maintaining suitable sedation during colonoscopy and reversing the sedative effects of remimazolam with flumazenil. METHODS: Healthy volunteers received fentanyl followed by remimazolam for sedation during colonoscopy. Three dose groups of 15 volunteers each received remimazolam in increasing initial doses, plus top-up doses to maintain sedation for a 30-minute period...
November 2013: Anesthesia and Analgesia
https://www.readbyqxmd.com/read/23820101/hypnotic-and-sedative-drugs-anything-new-on-the-horizon
#12
REVIEW
Tony Gin
PURPOSE OF REVIEW: Many studies of new intravenous sedative drugs have been published last year, including several phase I trials. This review provides a brief summary of these studies, with recommendations for selected reading. RECENT FINDINGS: Remimazolam is a rapidly metabolized benzodiazepine. Early clinical trials confirm more rapid recovery compared with midazolam. Etomidate analogues can be designed with rapid metabolism and without adrenocortical suppression, but research is only at the preclinical stage...
August 2013: Current Opinion in Anaesthesiology
https://www.readbyqxmd.com/read/23653886/anesthetic-drug-development-novel-drugs-and-new-approaches
#13
Hovig V Chitilian, Roderic G Eckenhoff, Douglas E Raines
The ideal sedative-hypnotic drug would be a rapidly titratable intravenous agent with a high therapeutic index and minimal side effects. The current efforts to develop such agents are primarily focused on modifying the structures of existing drugs to improve their pharmacodynamic and pharmacokinetic properties. Drugs currently under development using this rational design approach include analogues of midazolam, propofol, and etomidate, such as remimazolam, PF0713, and cyclopropyl methoxycarbonyl-etomidate (MOC-etomidate), respectively...
2013: Surgical Neurology International
https://www.readbyqxmd.com/read/22826518/remimazolam-new-beginnings-or-just-a-me-too
#14
EDITORIAL
J Robert Sneyd
No abstract text is available yet for this article.
August 2012: Anesthesia and Analgesia
https://www.readbyqxmd.com/read/22253270/a-placebo-and-midazolam-controlled-phase-i-single-ascending-dose-study-evaluating-the-safety-pharmacokinetics-and-pharmacodynamics-of-remimazolam-cns-7056-part-ii-population-pharmacokinetic-and-pharmacodynamic-modeling-and-simulation
#15
RANDOMIZED CONTROLLED TRIAL
Hugh R Wiltshire, Gavin J Kilpatrick, Gary S Tilbrook, Keith M Borkett
BACKGROUND: A new benzodiazepine, remimazolam, which is rapidly metabolized by tissue esterases to an inactive metabolite, has been developed to permit a fast onset, a short, predictable duration of sedative action, and a more rapid recovery profile than currently available drugs. We report on modeling of the data and simulations of dosage regimens for future study. METHODS: A phase I, single-center, double-blind, placebo and active controlled, randomized, single-dose escalation study was conducted...
August 2012: Anesthesia and Analgesia
https://www.readbyqxmd.com/read/22190555/a-placebo-and-midazolam-controlled-phase-i-single-ascending-dose-study-evaluating-the-safety-pharmacokinetics-and-pharmacodynamics-of-remimazolam-cns-7056-part-i-safety-efficacy-and-basic-pharmacokinetics
#16
RANDOMIZED CONTROLLED TRIAL
Laurie J Antonik, D Ronald Goldwater, Gavin J Kilpatrick, Gary S Tilbrook, Keith M Borkett
BACKGROUND: A new benzodiazepine, remimazolam, metabolized by tissue esterases to an inactive compound, CNS 7054, has been developed to permit a fast onset, a short and more predictable duration of sedative action, and a more rapid recovery profile than with currently available benzodiazepines. We report on the safety and efficacy of the first human study. METHODS: A phase I, single-center, double-blind, placebo- and active-controlled, randomized, single-dose escalation study was conducted...
August 2012: Anesthesia and Analgesia
https://www.readbyqxmd.com/read/21245208/enhancement-of-gabaergic-activity-neuropharmacological-effects-of-benzodiazepines-and-therapeutic-use-in-anesthesiology
#17
REVIEW
Teijo I Saari, Mikko Uusi-Oukari, Jouni Ahonen, Klaus T Olkkola
GABA is the major inhibitory neurotransmitter in the central nervous system (CNS). The type A GABA receptor (GABA(A)R) system is the primary pharmacological target for many drugs used in clinical anesthesia. The α1, β2, and γ2 subunit-containing GABA(A)Rs located in the various parts of CNS are thought to be involved in versatile effects caused by inhaled anesthetics and classic benzodiazepines (BZD), both of which are widely used in clinical anesthesiology. During the past decade, the emergence of tonic inhibitory conductance in extrasynaptic GABA(A)Rs has coincided with evidence showing that these receptors are highly sensitive to the sedatives and hypnotics used in anesthesia...
March 2011: Pharmacological Reviews
https://www.readbyqxmd.com/read/21154153/remimazolam-a-short-acting-gaba-a-receptor-agonist-for-intravenous-sedation-and-or-anesthesia-in-day-case-surgical-and-non-surgical-procedures
#18
REVIEW
William Kirke Rogers, Thomas S McDowell
Remimazolam (CNS-7056) is a short-acting GABA(A) receptor agonist, under development by PAION, in collaboration with Japanese licensee Ono Pharmaceutical, as an intravenous sedative agent for potential use in day-case procedures, and the induction and maintenance of anesthesia. A member of the benzodiazapene class of drugs, the structure of remimazolam was modified to produce a drug that displays organ-independent metabolism. The incorporation of a carboxylic ester moiety into the benzodiazapene core of remimazolam renders it susceptible to non-specific tissue esterases and it is rapidly metabolized into its pharmacologically inactive metabolite CNS-7054...
December 2010: IDrugs: the Investigational Drugs Journal
https://www.readbyqxmd.com/read/20852754/gateways-to-clinical-trials
#19
A Tomillero, M A Moral
A-3309, Abobotulinumtoxin A, Adalimumab, AIDSVAX gp120 B/E, ALVAC E120TMG, Atorvastatin calcium; Bepridil, Bevacizumab; Candesartan cilexetil, Capecitabine, Cetuximab, Clopidogrel; Dapagliflozin, Dasatinib, Denosumab, Dexmedetomidine hydrochloride, Diacetylmorphine, Diannexin, Docetaxel, Dutasteride; Entecavir, Eplerenone, Erlotinib hydrochloride, Escitalopram oxalate, Everolimus, Ezetimibe; Fesoterodine fumarate, Flagellin.HuM2e, Fluzone; Glimepiride/rosiglitazone maleate; Hyaluronic acid-paclitaxel bioconjugate; IDX-184, Imatinib mesylate, Infliximab, Insulin glargine, Irbesartan; JX-594; Landiolol, Latrunculin B, Levocetirizine dihydrochloride, Liraglutide, Lyprinol; Metformin, Metronidazole/tetracycline hydrochloride/bismuth biskalcitrate, Mipomersen sodium, Mycophenolic acid sodium salt; Nalfurafine hydrochloride, Nilotinib hydrochloride monohydrate; Paclitaxel nanoparticles, Paclitaxel poliglumex, Peginterferon alfa-2a, Peginterferon alfa-2b, Perospirone hydrochloride, Pimavanserin tartrate, Pirfenidone, Pitavastatin calcium, Prasterone, Prasugrel, Pregabalin, Ranelic acid distrontium salt, Ranibizumab, Remimazolam, Risedronate, Rosuvastatin calcium; Silodosin, Silybin phosphatidylcholine complex, Sirolimus-eluting stent, Sitagliptin phosphate monohydrate, Sorafenib, Sunitinib malate; Tadalafil, Tamsulosin hydrochloride, Technosphere/insulin, Telmisartan, Temsirolimus, Teriparatide, Thymalfasin, Ticagrelor, Toltedorine-XR, Tramadol-XR, Triphosadenine, Trospium-XR; Val8-GLP-1(7-37)OH, Valsartan, Vardenafil hydrochloride hydrate, Varenicline tartrate, Velaglucerase alfa; Zoledronic acid monohydrate...
July 2010: Methods and Findings in Experimental and Clinical Pharmacology
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"